Drug Profile
SV BR 1 GM cancer vaccine - BriaCell Therapeutics
Alternative Names: Allogeneic GM CSF secreting breast cancer vaccine - BriaCell Therapeutics; Bria-IMT™; BriaVax; GM CSF gene-transfected breast cancer vaccine - BriaCell Therapeutics; SV-BR-1 breast cancer cell line vaccine - BriaCell Therapeutics; SV-BR-1-GM; SV-BR-1-GM-vaccine-BriaCell-Therapeutics; SV-BR1-GM-breast-cancer-vaccine-BriaCell-TherapeuticsLatest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Wiseman Research Initiatives LLC
- Developer BriaCell Therapeutics Corp
- Class Antineoplastics; Cancer vaccines; Gene therapies; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Breast cancer
- No development reported Ovarian cancer
Most Recent Events
- 20 Dec 2023 Efficacy and adverse events data from phase I/II trials in Breast cancer released by BriaCell Therapeutics
- 05 Dec 2023 Efficacy, immunogenicity and adverse event data from a phase I/IIa trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 11 Oct 2023 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (Intradermal) (NCT06072612)